Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Минздрав России одобрил препарат Адцетрис® (брентуксимаб ведотин) для применения у ранее не получавших лечение взрослых пациентов с CD30-позитивными периферическими Т-клеточными лимфомами
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Клинические рекомендации. Нодальные Т-клеточные лимфомы. ID:КР138/1. 2020 г. Одобрено Научно-практическим cоветом Минздрава РФ [Klinicheskie rekomendatsii. Nodal'nye T-kletochnye limfomy. ID:KR138/1. 2020 g. Odobreno Nauchno-prakticheskim sovetom Minzdrava RF (in Russian)].
2. Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology fiand clinical outcomes. J Clin Oncol. 2008;26:4124-30.
3. Bellei M, Foss FM, Shustov AR, et al. The outcome of peripheral T-cell lymphoma patients failing fi-line therapy: a report from the prospective, International T-Cell Project. Haematologica. 2018;103:1191-7.
4. Mak V, Hamm J, Chhanabhai M, et al. Survival of patients with peripheral T-cell lymphoma after firelapse or progression: spectrum of disease and rare long-term survivors. Clin Oncol. 2013;31(16):1970-6.
5. Weisenburger DD, Savage KJ, Harris NL, et al. Peripheral T-cell lymphoma, not otherwise specified report of 340 cases from the International Peripheral T-cell Lymphoma Project. Blood. 2011;117:3402-8.
6. Bossard C, Dobay MP, Parrens M, et al. Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels. Blood. 2014;124:2983-6.
7. Federico M, Bellei M, Marcheselli L, et al. Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the International T cell Project Network. Br J Haematol. 2018;181:760-9.
8. Horwitz S, O'Connor OA, Pro B, et al. ECHELON-2 Study Group. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2019;393(10168):229‑40.
2. Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology fiand clinical outcomes. J Clin Oncol. 2008;26:4124-30.
3. Bellei M, Foss FM, Shustov AR, et al. The outcome of peripheral T-cell lymphoma patients failing fi-line therapy: a report from the prospective, International T-Cell Project. Haematologica. 2018;103:1191-7.
4. Mak V, Hamm J, Chhanabhai M, et al. Survival of patients with peripheral T-cell lymphoma after firelapse or progression: spectrum of disease and rare long-term survivors. Clin Oncol. 2013;31(16):1970-6.
5. Weisenburger DD, Savage KJ, Harris NL, et al. Peripheral T-cell lymphoma, not otherwise specified report of 340 cases from the International Peripheral T-cell Lymphoma Project. Blood. 2011;117:3402-8.
6. Bossard C, Dobay MP, Parrens M, et al. Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels. Blood. 2014;124:2983-6.
7. Federico M, Bellei M, Marcheselli L, et al. Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the International T cell Project Network. Br J Haematol. 2018;181:760-9.
8. Horwitz S, O'Connor OA, Pro B, et al. ECHELON-2 Study Group. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2019;393(10168):229‑40.
________________________________________________
1. Klinicheskie rekomendatsii. Nodal'nye T-kletochnye limfomy. ID:KR138/1. 2020 g. Odobreno Nauchno-prakticheskim sovetom Minzdrava RF (in Russian)
2. Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology fiand clinical outcomes. J Clin Oncol. 2008;26:4124-30.
3. Bellei M, Foss FM, Shustov AR, et al. The outcome of peripheral T-cell lymphoma patients failing fi-line therapy: a report from the prospective, International T-Cell Project. Haematologica. 2018;103:1191-7.
4. Mak V, Hamm J, Chhanabhai M, et al. Survival of patients with peripheral T-cell lymphoma after firelapse or progression: spectrum of disease and rare long-term survivors. Clin Oncol. 2013;31(16):1970-6.
5. Weisenburger DD, Savage KJ, Harris NL, et al. Peripheral T-cell lymphoma, not otherwise specified report of 340 cases from the International Peripheral T-cell Lymphoma Project. Blood. 2011;117:3402-8.
6. Bossard C, Dobay MP, Parrens M, et al. Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels. Blood. 2014;124:2983-6.
7. Federico M, Bellei M, Marcheselli L, et al. Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the International T cell Project Network. Br J Haematol. 2018;181:760-9.
8. Horwitz S, O'Connor OA, Pro B, et al. ECHELON-2 Study Group. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2019;393(10168):229‑40.
Авторы
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.